公开(公告)号：WO2011012901A1

公开(公告)日：2011-02-03

申请号：PCT/GB2010/051255

申请日：2010-07-29

Applicant: RANDOX LABORATORIES LTD ,  RUDDOCK, Mark, W. ,  REID, Cherith, N. ,  WILLIAMSON, Kathleen ,  LAMONT, John, V. ,  FITZGERALD, Stephen, P

Inventor： RUDDOCK, Mark, W. ,  REID, Cherith, N. ,  WILLIAMSON, Kathleen ,  LAMONT, John, V. ,  FITZGERALD, Stephen, P

IPC: G01N33/574

CPC classification number: G01N33/57407 ,  G01N2800/34

Abstract: The present invention provides a method for the detection of, or the risk of, bladder cancer in a patient, comprising the step of detecting the presence of a combination of at least two biomarkers selected from CEA, VEGF, IL-8, NGAL, NSE, IL-2, EGF, TM, d-Dimer, MMP-9, IL-6, IL-4, MMP-9/NGAL, FAS, CRP, TUP and NMP22 in one or more samples isolated from a patient wherein the presence of a combination of at least two biomarkers in the one or more samples indicates the presence or risk of bladder cancer.

Abstract translation: 本发明提供了一种检测患者膀胱癌或其风险的方法，包括检测选自CEA，VEGF，IL-8，NGAL，NSE的至少两种生物标志物的组合的存在的步骤 ，IL-2，EGF，TM，d-二聚体，MMP-9，IL-6，IL-4，MMP-9 / NGAL，FAS，CRP，TUP和NMP22在从患者分离的一个或多个样品中 在一个或多个样品中至少两个生物标志物的组合指示膀胱癌的存在或风险。

公开(公告)号：WO2020099895A1

公开(公告)日：2020-05-22

申请号：PCT/GB2019/053253

申请日：2019-11-15

Applicant: RANDOX LABORATORIES LTD

Inventor： RUDDOCK, Mark ,  LAMONT, John ,  FITZGERALD, Stephen ,  WILLIAMSON, Kathleen

IPC: G01N33/574

Abstract: The present invention provides a method for detecting the presence or risk of bladder cancer in a female patient comprising the steps of detecting the presence of a panel of biomarkers in a sample isolated from a female patient, said panel of biomarkers comprising IL-13 and IL-12p70 and one or more biomarkers selected from BTA, Midkine, PAI-1/t PA, 8OHdG, CEA, CK18, Clusterin, Creatinine, CXCL16, Cystatin B, Cystatin C, d-Dimer, EGF, FAS, HAD, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8, MCP-1, Microalbumin, MMP9NGAL, MMP9TIMP1, NGAL, NSE, Progranulin, TUP, TGFB1, Thrombomodulin, sTNFR1, TPA, VEGF and Triglycerides and/or the concentration of albumin/microalbumin/protein and creatinine expressed as an albumin:creatinine ratio in a sample i s o l a t e d f r o m a female patient; and assessing the results and comparing them to a normal control wherein an elevated presence of the biomarker compared to a normal control indicates the presence or risk of cancer in the patient from whom the sample is isolated.

公开(公告)号：WO2015150834A1

公开(公告)日：2015-10-08

申请号：PCT/GB2015/051053

申请日：2015-04-02

Applicant: RANDOX LABORATORIES LTD.

Inventor： RUDDOCK, Mark ,  REID, Cherith ,  LAMONT, John ,  FITZGERALD, Stephen ,  DE MATOS SIMOES, Ricardo ,  WILLIAMSON, Kathleen

IPC: G01N33/574 ,  G01N33/68

CPC classification number: G01N33/57407 ,  G01N33/543 ,  G01N33/57488 ,  G01N33/577 ,  G01N33/6869 ,  G01N2333/485 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/545

Abstract: The present invention provides a method and a solid state device for identifying the presence of urothelial cancer in a patient comprising assigning the subject to a sub-population according to smoking habits, measuring the level of each biomarker of a panel of biomarkers in one or more samples obtained from the subject; and correlating the measured levels of the panel of biomarkers with the likelihood of the subject having urothelial cancer such that the subject can be classified as having urothelial cancer or as being a control.

Abstract translation: 本发明提供一种用于鉴定患者中尿路上皮癌的存在的方法和固态装置，包括根据吸烟习惯将受试者分配给亚群体，测量一个或多个生物标志物组中每个生物标志物的水平 从受试者获得的样品; 并将生物标志物组的测量水平与受试者具有尿路上皮癌的可能性相关联，使得受试者可以分类为具有尿路上皮癌或作为对照。